19 / 76
CARDIOVASCULAR JOURNAL OF AFRICA • Volume 27, No 6, November/December 2016
AFRICA
349
to whether complete resorption of the BVS over two years will
affect the clinical outcomes. However, short-term clinical results
are promising.
Conclusion
BVS implantation appears to be effective and safe in CTO
lesions, according to our results, but randomised studies with
a larger number of patients and a longer follow up are needed.
References
1.
Di Mario C, Werner GS, Sianos G,
et al
. European perspective in the
recanalisation of chronic total occlusions (CTO): consensus document
from the EuroCTO Club.
EuroIntervention
2007;
3
(1): 30–43.
2.
Fefer P, Knudtson ML, Cheema AN,
et al
. The Canadian Multicenter
Chronic Total Occlusions Registry. Current perspectives on coronary
chronic total occlusions.
J Am Coll Cardiol Mar
2012;
59
(11): 991–997.
3.
Claessen BE, Dangas GD, Godino C,
et al
. Long-term clinical outcomes
of percutaneous coronary intervention for chronic total occlusions in
patients with vs. without diabetes mellitus.
Am J Cardiol
2011;
108
(7):
924–931.
4.
Joyal D, Afilalo J, Rinfret S. Effectiveness of recanalization of chronic
total occlu- sions: a systematic review and meta-analysis.
Am Heart J
2010;
160
(1): 179–187.
5.
Grantham JA, Jones PG, Cannon L, Spertus JA. Quantifying the
early health status benefits of successful chronic total occlusion reca-
nalization: Results from the Flow-Cardia’s Approach to Chronic Total
Occlusion Recanalization (FACTOR) Trial.
Circ Cardiovasc Qual
Outcomes
2010;
3
(3): 284–290.
6.
Windecker S, Kolh P, Alfonso F,
et al.
2014 ESC/EACTS Guidelines
on myocardial revascularization: The Task Force on Myocardial
Revascularization of the European Society of Cardiology (ESC) and
the European Association for Cardio-Thoracic Surgery (EACTS).
Developed with the special contribution of the European Association
of Percutaneous Cardiovascular Interventions (EAPCI).
Eur Heart J
2014;
35
(37): 2541–2619.
7.
Colmenarez HJ, Escaned J, Fernandez C,
et al
. Efficacy and safety of
drug-eluting stents in chronic total coronary occlusion recanalization:
a systematic review and meta-analysis
. J Am Coll Cardiol
2010;
55
(17):
1854–1866.
8.
Patel MR, Marso SP, Dai D,
et al.
Comparative effectiveness of drug-
eluting vs. bare-metal stents in elderly patients undergoing revasculari-
zation of chronic total coronary occlusions: results from the National
Cardiovascular Data Registry, 2005–2008.
J Am Coll Cardiol Cardiovasc
Interv
2012;
5
(10): 1054–1061.
9.
Serruys PW, Chevalier B, Dudek D,
et al
. A bioresorbable everolimus-
eluting scaffold versus a metallic everolimus-eluting stent for ischae-
mic heart disease caused by
de-novo
native coronary artery lesions
(ABSORB II): an interim 1-year analysis of clinical and procedural
secondary outcomes from a randomised controlled trial.
Lancet
2015;
385
: 43–54.
10. Ellis SG, Kereiakes DJ, Metzger DC,
et al
. Everolimus-eluting biore-
sorbable scaffolds for coronary artery disease.
N Engl J Med
2015, Oct
12. [Epub ahead of print].
11. Kimura T, Kozuma K, Tanabe K,
et al
. A randomized trial evaluating
everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting
metallic stents in patients with coronary artery disease: ABSORB Japan
.
Eur Heart J
2015, Sep 1. pii: ehv435. [Epub ahead of print].
12. Serruys PW, Ormiston JA, Onuma Y,
et al
. A bioabsorbable everolimus-
eluting coronary stent system (ABSORB): 2-year outcomes and results
from multiple imaging methods
. Lancet
2009;
373
(9667): 897–910.
13. Dudek D, Onuma Y, Ormiston JA,
et al
. Four-year clinical follow-up
of the ABSORB everolimus-eluting bioresorbable vascular scaffold
in patients with
de novo
coronary artery disease: the ABSORB trial.
EuroIntervention
2012;
7
: 1060–1061.
14. Wiebe J, Liebetrau C, Dörr O,
et al
. Feasibility of everolimus-eluting
bioresorbable vascular scaffolds in patients with chronic total occlusion.
Int J Cardiol
2015;
179
: 90–94.
15. Goktekin O, Yamac AH, Latib A,
et al
. Evaluation of the safety of
everolimus-eluting bioresorbable vascular scaffold (BVS) implantation
in patients with chronic total coronary occlusions: acute procedural and
short-term clinical results.
J Invasive Cardiol
2015;
27
: 461–466.
16. Ojeda S, Pan M, Romero M,
et al
. Outcomes and computed tomography
scan follow-up of bioresorbable vascular scaffold for the percutaneous
treatment of chronic total coronary artery occlusion.
Am J Cardiol
2015;
115
: 1487–1493.
17. Rama-Merchan JC, Mattesini A, Dall’Ara G, Mario CD. Chronic total
occlusion successfully treated with a bioresorbable everolimus-eluting
vascular scaffold.
Postepy Kardiol Interwencyjnej
2014;
10
: 128–129.
18. Galassi AR, Brilakis ES, Boukhris M,
et al
. Appropriateness of percu-
taneous revascularization of coronary chronic total occlusions: an
overview.
Eur Heart J
2015, Aug 7. pii: ehv391. [Epub ahead of print].
19. Ito T, Tsuchikane E, Nasu K,
et al
. Impact of lesion morphology on
angiographic and clinical outcomes in patients with chronic total occlu-
sion after recanalization with drug-eluting stents: a multislice computed
tomography study.
Eur Radiol
2015;
25
: 3084–3092.
20. Özel E, Ta
ş
tan A, Öztürk A, Özcan EE, Uyar S,
Ş
enarslan Ö. What is
better for predilatation in bioresorbable vascular scaffold implantation:
a non-compliant or a compliant balloon?
Anatol J Cardiol
2015, Jun 18.
doi:10.5152/Anatol J Cardiol.2015.6184. [Epub ahead of print].
21. Caiazzo G, Kilic ID, Fabris E,
et al
. Absorb bioresorbable vascular
scaffold: What have we learned after 5 years of clinical experience?
Int J
Cardiol
2015;
201
: 129–136.
22. Tamburino C, Latib A, van Geuns RJ,
et al
. Contemporary practice and
technical aspects in coronary intervention with bioresorbable scaffolds:
a European perspective.
EuroIntervention
2015;
11
: 45–52.
23. Morino Y, Abe M, Morimoto T,
et al
. Predicting successful guidewire
crossing through chronic total occlusion of native coronary lesions
within 30 minutes: the J-CTO (Multicenter CTO Registry in Japan)
score as a difficulty grading and time assessment tool.
J Am Coll Cardiol
Cardiovasc Interv
2011;
4
: 213–221.